Literature DB >> 28364817

Management of Immunosuppression in Liver Transplantation.

Renumathy Dhanasekaran1.   

Abstract

Liver transplantation outcomes have significantly improved over the past few decades owing largely to the introduction of effective immunosuppression medications. Further comprehension of the unique immune microenvironment of the liver has led to the development of newer molecular targeted therapeutics. Understanding the mechanism of action and adverse effect profiles of these medications is crucial for appropriate management of posttransplant patients. In this review, the author describes the immunologic response elicited by liver transplantation, chronicles the various immunosuppressant drug classes, discusses the evidence behind their use, and evaluates the management of special subpopulations of posttransplantation patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calcineurin; Hepatitis C; Immunosuppression; Rejection; Transplantation

Mesh:

Substances:

Year:  2017        PMID: 28364817     DOI: 10.1016/j.cld.2016.12.007

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  6 in total

1.  Differences in Liver Graft Survival by Recipient Sex.

Authors:  Alexia I De Simone; Xun Zhang; Mourad Dahhou; Ruth Sapir-Pichhadze; Heloise Cardinal; Vicky Ng; Bethany J Foster
Journal:  Transplant Direct       Date:  2020-11-10

Review 2.  Implantable Immunosuppressant Delivery to Prevent Rejection in Transplantation.

Authors:  Madonna Rica Anggelia; Ren-Wen Huang; Hui-Yun Cheng; Chih-Hung Lin; Cheng-Hung Lin
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

Review 3.  Immunological Tolerance in Liver Transplant Recipients: Putative Involvement of Neuroendocrine-Immune Interactions.

Authors:  Jaciara Fernanda Gomes Gama; Liana Monteiro da Fonseca Cardoso; Rodrigo da Cunha Bisaggio; Jussara Lagrota-Candido; Andrea Henriques-Pons; Luiz A Alves
Journal:  Cells       Date:  2022-07-29       Impact factor: 7.666

4.  Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria.

Authors:  Sunbin Ling; Tingting Feng; Qifan Zhan; Xin Duan; Guangjiang Jiang; Tian Shen; Qiaonan Shan; Shengjun Xu; Qianwei Ye; Peng Liu; Beini Cen; Shusen Zheng; Xiao Xu
Journal:  Ann Transl Med       Date:  2020-02

Review 5.  Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment.

Authors:  Maria J Peláez-Jaramillo; Allison A Cárdenas-Mojica; Paula V Gaete; Carlos O Mendivil
Journal:  Diabetes Ther       Date:  2018-02-06       Impact factor: 2.945

6.  Center-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns Analysis.

Authors:  Mustafa Nazzal; Krista L Lentine; Abhijit S Naik; Rosemary Ouseph; Mark A Schnitzler; Zidong Zhang; Henry Randall; Vikas R Dharnidharka; Dorry L Segev; Bertram L Kasiske; Gregory P Hess; Tarek Alhamad; Mara McAdams-Demarco; David A Axelrod
Journal:  Transplant Direct       Date:  2018-06-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.